A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

15922ABLE-32-NCT06510374OpenA Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerABLE-32NCT06510374IndustrialAdultTreatmentIIIUrinary BladderGupta, MohitGeorgetown University Medical Center : Beth Mekonen; Lombardi Comprehensive Cancer Center : Beth MekonenGenito-urinaryOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS16061Beth MekonenBeth Mekonenbam159@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>